2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1283

Power Doppler Ultrasound Phenotyping of Expanding Versus Collapsed Popliteal Lymph Nodes in Murine Inflammatory Arthritis
Abstract Number: 2108

Pre- and Postoperative Physical Therapy In Total Hip and Knee Replacement Surgery: A Multi Center Study
Abstract Number: 1287

Pre-Clinical Proof-Of-Concept Of ALX-0761, a Nanobody^® Neutralizing Both IL-17A and F In a Cynomolgus Monkey Collagen Induced Arthritis Model
Abstract Number: 40

Preclinical Characterization Of a Humanized Antagonistic Anti-CD40 Mab
Abstract Number: 1334

Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial
Abstract Number: 2152

Predicting Benefit From Lateral Wedge Orthotics Using Radiographic Parameters In Medial Knee Osteoarthritis
Abstract Number: 2480

Predicting Progression Of Non-Radiographic Axial Spondyloarthritis
Abstract Number: 168

Predicting The Severity Of Joint Damage In Rheumatoid Arthritis; The Contribution Of Genetic Factors
Abstract Number: 1745

Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation
Abstract Number: 876

Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling
Abstract Number: 431

Prediction Of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment
Abstract Number: 702

Prediction Of Worsening Of Skin Fibrosis In Patients With Diffuse Systemic Sclerosis Using The EULAR Scleroderma Trials and Research (EUSTAR) Registry
Abstract Number: 2388

Predictive Factors Of Relapse Or Persistent Stable Remission For Rheumatoid Arthritis (RA) Patients In Remission in a TNF Blocker-Spacing Strategy Trial (STRASS Trial)
Abstract Number: 1441

Predictive Factors Of Response To Tocilizumab In Patients With Active Rheumatoid Arthritis
Abstract Number: 272

Predictive Markers Of Joint Damages Of Children With Systemic-Onset Juvenile Idiopathic Arthritis In Long-Term Course Of Treatment With Tocilizumab

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].